Lantus Cost in Delaware 2026: Prices, Coverage, and How to Pay Less

What Does Lantus Actually Cost in Delaware Right Now?

Sanofi's published list price for Lantus is $340 per month, but almost no Delaware patient pays that figure. With a GoodRx or SingleCare coupon at major Delaware chains, the cash price drops to approximately $35 per month for a 10 mL vial of insulin glargine 100 units/mL. The gap between list and street price is large enough that understanding each payment option saves hundreds of dollars per year.

Pharmacy pricing in Delaware follows national wholesale acquisition cost (WAC) tables set by Sanofi, then adjusted by each chain's negotiated rates. Because insulin pricing has been a target of federal scrutiny, Sanofi voluntarily capped its net price in 2023. The Inflation Reduction Act of 2022 also set a $35 out-of-pocket cap on insulin for Medicare Part D beneficiaries beginning January 2023, a change that directly benefits Delaware's estimated 14,000+ Medicare insulin users [1].

Retail prices vary by pharmacy within Delaware. Walgreens, CVS, Rite Aid, and independent Delaware pharmacies each apply different dispensing fees. Running a GoodRx search before presenting your prescription can reduce the out-of-pocket cost at CVS Pharmacy in Wilmington to as low as $32 for a 10 mL vial, compared with $41 without a coupon. The FDA maintains updated labeling and pricing reference information for Lantus on its drug database [2].

Switching to an FDA-approved biosimilar such as Semglee (insulin glargine-yfgn, Viatris) may reduce costs further. Semglee is interchangeable with Lantus by FDA designation, meaning a Delaware pharmacist can substitute it without a new prescription [3]. The average cash price for Semglee in Delaware runs approximately $25 per month with a discount card, roughly $10 less than branded Lantus. Basaglar (insulin glargine, Lilly) is another approved alternative priced similarly [4].

The clinical evidence supporting glargine therapy is substantial. The ORIGIN trial (N=12,537) published in the New England Journal of Medicine in 2012 showed that basal insulin glargine targeting a fasting glucose of 95 mg/dL or less did not increase rates of cardiovascular events versus standard care over a median of 6.2 years, with a hazard ratio of 1.02 (95% CI 0.94 to 1.11) [5]. That long-term safety dataset remains one of the largest for any basal insulin and gives clinicians confidence prescribing glargine to patients with type 2 diabetes who also carry cardiovascular risk.

Delaware Medicaid Coverage for Lantus

Delaware Medicaid (Diamond State Health Plan and its managed care partners) covers insulin glargine with a prior authorization requirement. PA criteria typically require documentation of a type 1 or type 2 diabetes diagnosis, a prescriber attestation that the patient has tried at least one formulary-preferred insulin, and a clinical note justifying the brand choice if a biosimilar is available [6].

For type 1 diabetes, PA approval rates are high because the clinical need is straightforward. For type 2 diabetes, a prescriber may need to demonstrate that NPH insulin was inadequate or caused hypoglycemia before Medicaid will approve Lantus at no cost to the patient. Delaware's Medicaid formulary is published annually by the Division of Medicaid and Medical Assistance (DMMA) and updated each January.

Once approved, Delaware Medicaid patients typically pay $0 to $3 per 30-day supply under the federal upper limit rules for insulin, making Medicaid coverage the lowest-cost pathway available in the state. Patients can check their specific plan tier and copay through the Delaware Benefits portal at benefits.delaware.gov or by calling the DMMA helpline.

Physicians and advanced practice providers enrolled with Delaware Medicaid can submit PA requests electronically through the state's CoverMyMeds gateway. Turnaround is generally 3 to 5 business days for standard requests, or 24 hours for urgent submissions when a prescriber documents clinical urgency such as new-onset type 1 diabetes. The American Diabetes Association's Standards of Medical Care note that "access to affordable insulin is a matter of life and death for people with diabetes," a statement from the 2024 Standards [7] that Delaware Medicaid policy indirectly addresses through its covered drug list.

Is Compounded Insulin Glargine Legal in Delaware?

Compounded insulin glargine is legal in Delaware when prepared by a state-licensed 503A compounding pharmacy operating under a valid patient-specific prescription. A 503A pharmacy compounds for individual patients, as distinguished from 503B outsourcing facilities that produce bulk product. Delaware's Board of Pharmacy enforces USP 797 sterile compounding standards, which govern beyond-use dating, sterility testing, and facility requirements for any compounded injectable [8].

The FDA has not approved compounded insulin glargine as a finished drug product, so the compounded version is not bioequivalent-certified the way Semglee is. That distinction matters clinically. Prescribers should document the medical rationale for choosing a compounded product over an FDA-approved biosimilar.

Pricing for compounded insulin glargine varies by pharmacy, but some Delaware-accessible compounding pharmacies quote costs as low as $0 per month for patients whose prescribers participate in specific programs, or $20 to $60 per month when paid out of pocket. These prices are substantially below branded Lantus but come without the FDA bioequivalence guarantee [9].

Patients in Delaware who want compounded glargine should verify three things with the compounding pharmacy: (1) the pharmacy holds a current Delaware Board of Pharmacy license, (2) it follows USP 797 sterile compounding guidelines, and (3) it can provide a certificate of analysis for each batch. Requesting that documentation is standard practice and any reputable 503A pharmacy will supply it without hesitation.

Biosimilar Options Available in Delaware Pharmacies

Three FDA-approved interchangeable or biosimilar glargine products are stocked at Delaware retail pharmacies. Semglee received FDA interchangeability designation in 2021, meaning automatic substitution by a pharmacist is lawful in Delaware [3]. Basaglar (Lilly) was approved as a follow-on biologic in 2015 and carries a cash price near $26 per month with a discount card. Rezvoglar (Lilly) launched in 2023 at a list price of $92 per vial, approximately 78% below Lantus list price.

When a prescriber writes "insulin glargine" without specifying a brand, a Delaware pharmacist can dispense any of these interchangeable products. Patients who want the lowest cash price should ask the pharmacist to check all available biosimilars before dispensing. The FDA's biosimilar product information database provides current interchangeability status for each product [10].

Biosimilar uptake has been slower than regulators expected. A 2023 JAMA Internal Medicine analysis found that biosimilar insulin penetration in commercial pharmacy claims remained below 30% three years after Semglee's approval, largely because formulary placement decisions by pharmacy benefit managers lagged behind FDA approvals [11]. Delaware patients on commercial insurance should ask their plan specifically whether Semglee or Basaglar is tier-preferred over branded Lantus, because that tier placement determines the copay difference.

Savings Programs That Work in Delaware

Several programs reduce the out-of-pocket cost of Lantus for Delaware residents who do not qualify for Medicaid or whose commercial insurance does not cover glargine adequately.

Sanofi Insulins Valyou Savings Program. Uninsured or underinsured Delaware patients can enroll at insulins.us.sanofi.com. The program caps out-of-pocket cost at $99 per month for Lantus and other Sanofi insulins. Income documentation is not required [12]. Enrollment takes about 10 minutes online.

Sanofi Patient Assistance Program (PAP). Patients below 400% of the federal poverty level who lack insurance coverage may qualify for free Lantus through Sanofi's PAP. Applications are submitted through NeedyMeds or directly through Sanofi's patient access team. Processing time is typically 2 to 4 weeks.

GoodRx and SingleCare discount cards. These are free to obtain and reduce the cash price at most Delaware pharmacies to approximately $35 per month for a 10 mL vial of glargine 100 units/mL. Neither card requires insurance enrollment.

Delaware Prescription Assistance Program (DPAP). The Delaware Health and Social Services agency administers DPAP for state residents who earn too much for Medicaid but cannot afford prescription costs. DPAP can supplement copay costs for covered drugs including insulin. Applications are available at dhss.delaware.gov [13].

Medicare Extra Help (Low Income Subsidy). Delaware Medicare beneficiaries with limited income and resources may qualify for Extra Help, which reduces Part D insulin costs to near $0. The Social Security Administration administers enrollment, and the Delaware Medicare Assistance Bureau (DMAB) offers free counseling to help residents apply [14].

The HealthRX Delaware Insulin Cost Decision Framework guides patients through the following sequence: (1) Confirm insurance status and check the formulary tier for glargine. (2) If covered, calculate the copay versus the Sanofi Valyou cap. (3) If uninsured, compare the GoodRx cash price for Lantus versus Semglee versus compounded glargine at a 503A pharmacy. (4) If income qualifies, apply for DPAP or the Sanofi PAP before the next refill date. This four-step process takes most Delaware patients from list price to an optimized cost within one prescription cycle.

Telehealth Prescribing of Lantus in Delaware

Delaware law permits telehealth prescribing of insulin glargine. A licensed Delaware physician, physician assistant, or advanced practice nurse can conduct a synchronous audio-video visit, review blood glucose logs and A1C results, and issue a valid electronic prescription for Lantus without an in-person visit [15]. Controlled substance rules do not apply to insulin, so the Ryan Haight Act restrictions are not relevant here.

HealthRX connects Delaware patients with board-certified endocrinologists and internal medicine physicians who prescribe insulin as part of a comprehensive diabetes management plan. A telehealth visit typically takes 20 to 45 minutes. The prescriber reviews continuous glucose monitor (CGM) or glucometer data, titrates the glargine dose, and sends the prescription electronically to any licensed Delaware pharmacy.

For patients on Medicare in Delaware, telehealth coverage for diabetes management expanded permanently after the Consolidated Appropriations Act of 2023 removed the geographic restriction that previously limited telehealth to rural areas [16]. Delaware Medicare patients can now receive insulin prescribing and diabetes education via telehealth from any location within the state.

Commercial Insurance Coverage for Lantus in Delaware

The major commercial insurers operating in Delaware include Highmark Blue Cross Blue Shield of Delaware, Aetna, Cigna, UnitedHealthcare, and Clover Health (Medicare Advantage). Each maintains its own formulary tier for insulin glargine products.

Highmark BCBS Delaware typically places Semglee on Tier 2 (preferred brand) and Lantus on Tier 3 (non-preferred brand) for most employer-sponsored plans, meaning Lantus carries a higher copay. A Delaware employee with a standard Highmark plan may pay $15 to $30 for Semglee versus $45 to $60 for Lantus per 30-day supply, depending on plan design. Checking the specific plan's Summary of Benefits and Coverage (SBC) at the time of open enrollment is the most reliable way to confirm the current tier.

Aetna and UnitedHealthcare Delaware plan formularies follow similar logic, preferring biosimilars to contain costs. Cigna has placed Basaglar in the preferred tier on several Delaware employer plans since 2020. A 2022 analysis in Diabetes Care found that formulary tier placement was the single strongest predictor of biosimilar insulin uptake in commercially insured populations, stronger than prescriber preference or patient education [17].

If a Delaware patient's plan places Lantus on a non-preferred tier, the prescriber can submit a formulary exception request citing medical necessity. Acceptable grounds include documented hypoglycemia on an alternative basal insulin, allergy to excipients in the preferred product, or documented therapeutic failure. Most Delaware commercial plans respond to formulary exception requests within 72 hours.

Dosing and Administration Basics for New Delaware Patients

Insulin glargine is injected subcutaneously once daily, at the same time each day. Starting doses for type 2 diabetes are typically 10 units per day, adjusted upward by 2 units every 3 days until fasting glucose reaches the target range specified by the prescriber, generally 80 to 130 mg/dL per the American Diabetes Association 2024 Standards [7]. Type 1 diabetes dosing follows a more individualized calculation based on total daily insulin requirements.

Lantus must not be mixed with any other insulin in the same syringe. It is a clear, colorless solution; any cloudiness or particles indicate the vial should be discarded. Unopened vials should be refrigerated at 36 to 46 degrees Fahrenheit. After first use, a vial may be stored at room temperature (below 77 degrees Fahrenheit) for up to 28 days [2].

Injection sites include the abdomen, thigh, or upper arm. Rotating sites within the same region reduces lipohypertrophy, a common complication that slows insulin absorption. A Delaware patient starting glargine for the first time should receive structured diabetes self-management education (DSME), which Delaware Medicaid covers as a separate benefit under the DSME benefit category [18].

The most common adverse effect is hypoglycemia, particularly during dose titration. The ORIGIN trial reported a rate of 1.00 severe hypoglycemic event per 100 person-years in the glargine group versus 0.31 per 100 person-years in the standard-care group [5], a meaningful but manageable difference when patients are educated on recognition and treatment of low blood glucose.

What the ORIGIN Trial Means for Delaware Patients Considering Glargine

The ORIGIN trial remains the most clinically significant long-term study of basal insulin in people with early dysglycemia. Its 12,537 participants were randomized to insulin glargine targeting fasting glucose of 95 mg/dL or less, or to standard care, and followed for a median of 6.2 years. The trial showed no increase in cancer incidence, no increase in major cardiovascular events, and a 28% lower risk of progressing to frank type 2 diabetes from impaired fasting glucose or impaired glucose tolerance in the glargine arm [5].

The trial was conducted before FDA biosimilar approval for glargine, so all participants received branded Lantus. The pharmacodynamic profile of FDA-approved interchangeable biosimilars such as Semglee is clinically equivalent per the FDA's stringent biosimilarity standard [3], meaning the ORIGIN cardiovascular and glycemic data are applicable to patients using biosimilar glargine today.

For a Delaware patient deciding between branded Lantus, Semglee, Basaglar, or compounded glargine, the ORIGIN data support confidence in glargine's safety profile regardless of which approved product is dispensed. The trial's principal investigator noted that the cardiovascular neutrality finding "should reassure clinicians and patients that using basal insulin to control fasting glucose does not carry hidden cardiovascular risk" [5].

How to Get Started with Insulin Glargine in Delaware

Delaware residents who need insulin glargine can follow a straightforward path. Schedule a telehealth visit with a HealthRX-affiliated prescriber, provide your most recent A1C and fasting glucose records, and confirm your insurance or preferred payment method before the visit. The prescriber will determine whether Lantus, a biosimilar, or a different basal insulin is appropriate for your clinical situation.

If cost is the primary concern, tell the prescriber explicitly. A board-certified physician can document medical necessity for a biosimilar, write the prescription to allow pharmacist substitution, and simultaneously submit a Sanofi PAP application if income criteria are met. Combining the DPAP benefit with a GoodRx coupon at a Delaware pharmacy brings the monthly cost for glargine to $35 or below for most uninsured patients.

Delaware's Division of Public Health maintains a list of diabetes education programs recognized by the American Diabetes Association, available through the state's diabetes prevention and control program. Attending at least one structured DSME session is associated with a 0.76-percentage-point reduction in A1C at 6 months per a 2021 Cochrane review of 116 randomized trials (N=24,378) [19], a clinically meaningful improvement for patients starting any basal insulin.

For Medicare beneficiaries in Delaware, the $35 per month Part D insulin cap means branded Lantus and biosimilar glargine cost the same out of pocket, removing any financial incentive to switch products. In that case, therapeutic preference and prescriber familiarity with the product should guide the choice [20].